Focused on the Cure
Find out more about Cell Therapy
What is CAR T-cell therapy?
Chimeric antigen receptor (CAR) T-cell therapy is an individualised treatment where T cells (type of white blood cell) are removed from a patient and modified so they can recognise and target cancer cells. The engineered cells are then returned to the same patient.
Patient eligibility
Who is CAR T treatment for?
CAR T-cell therapy is a specialised treatment option for patients with specific difficult-to-treat
blood cancers who do not respond to (refractory) or fail (relapsed) initial treatment. Patients
should speak to their doctor or other relevant healthcare for specific, health-related
advice and support.
CAR T-cell therapy has been studied in patients with a range of blood cancers, including diffuse
large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade
B-cell lymphoma (HGBL), acute lymphoblastic leukaemia (ALL), follicular lymphoma (FL), mantle
cell lymphoma (MCL) and multiple myeloma (MM).
Given its complex process, CAR T-cell therapy must be administered at a qualified treatment
centre where healthcare professionals have undergone a rigorous training process.
How does CAR T-cell therapy work?
The mechanism of action of CAR T-cell therapy
CAR T-cell therapy is an individualised treatment that is changing the way cancer is treated. Cell therapy technology uses the power of a patient's own immune system to attack certain types of cancer cells.
Events and Congress
Click here to learn more about Gilead and Kite's presence at the events and congresses including the latest abstracts and posters.
Learn morePatient Videos